Avedro (NASDAQ:AVDR)‘s stock had its “market perform” rating reissued by equities research analysts at Svb Leerink in a research note issued on Tuesday, Marketbeat Ratings reports. They currently have a $22.00 price objective on the stock, down from their previous price objective of $25.00. Svb Leerink’s target price suggests a potential upside of 0.55% from the company’s previous close. Svb Leerink also issued estimates for Avedro’s Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($2.13) EPS, Q1 2020 earnings at ($0.51) EPS, FY2020 earnings at ($1.74) EPS and FY2022 earnings at ($0.05) EPS.
A number of other research analysts have also weighed in on AVDR. Leerink Swann lowered shares of Avedro from an “outperform” rating to a “market perform” rating and set a $22.00 target price on the stock. in a research note on Monday. Cowen lowered shares of Avedro from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $25.00 to $27.00 in a research note on Thursday, August 8th. Finally, Zacks Investment Research raised shares of Avedro from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Monday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $24.00.
AVDR opened at $21.88 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 9.60 and a quick ratio of 9.09. The business has a 50 day simple moving average of $19.57. Avedro has a 1-year low of $10.75 and a 1-year high of $24.74. The stock has a market cap of $373.72 million and a price-to-earnings ratio of -1.22.
Avedro Company Profile
Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.
Featured Article: Can systematic risk be avoided?
Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.